Advocacy Lead, Clinical Trial Abundance

1Day Sooner represents altruistic medical research participants. We have run successful advocacy campaigns in the U.S. (at both the federal and state levels), U.K., and Africa which have collectively impacted billions of dollars in spending and been covered globally in outlets such as the New York Times, CNN, the BBC, and Nature Magazine. We are looking for an Advocacy Lead to manage our in-house advocacy for our US campaigns. The Advocacy Lead owns our government relations, especially with Congress, and manages our federal advocacy strategy (including stakeholder and legislative recruitment, grassroots outreach, events, and press), meets with legislative teams and other decision-makers in DC, and coordinates the creation of advocacy materials and the answering of decision-maker questions and objections. The Advocacy Lead is 1Day’s day-to-day lead on the Hill, connecting 1Day’s policy and research teams with our lobbying firm while developing campaign strategy with our Director of Science Policy and Advocacy and our President.

Currently, 1Day’s main advocacy campaign is for “Clinical Trial Abundance", a movement that seeks to reduce the cost of health evidence and extract more value from the evidence we have. Our program seeks to both: (1) achieve incremental policy change through legislative vehicles such as the Prescription Drug User Fee Act as well as regulatory rulemaking and guidance; and (2) build a broader movement to achieve transformative change over time. Our vision for the next ten years is to reshape the FDA of the 21st century as profoundly as the post-thalidomide era changed the FDA of the 20th. The idealized stretch goal is to, within the next ten years, increase the amount and value of health evidence being generated by 10x at 1/10th the current average cost. In October 2026, Reps. Auchincloss and Griffith introduced the bipartisan Faster Clinical Trials Act, which carries four of our priorities into statute text: fair compensation for trial participants, public summaries of IRB decisions, continued publication of FDA complete response letters, and real-world evidence guidance. We are now building a coalition behind the bill and working toward a Senate companion and next year’s PDUFA reauthorization.

Please see our posting on Recruitee for complete information about this posting.